# BPC-157

> Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.

- Also known as: Body Protective Compound 157, PL 14736
- Class: Healing & Repair
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/bpc-157

## Overview

BPC-157 is a 15-amino-acid sequence derived from a protective protein found in human gastric juice. Preclinical work suggests pro-angiogenic and cytoprotective activity across tendon, ligament, muscle, and GI tissue.

BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid sequence derived from a protective protein identified in human gastric juice. It is studied as a cytoprotective and pro-angiogenic agent, with most of the interest centered on connective-tissue and gastrointestinal repair.

Essentially all of the evidence is preclinical — cell cultures and rodent models — and BPC-157 is not approved by the FDA for any use. It is widely discussed in the tissue-repair literature but lacks the controlled human trials that characterize approved peptides, so model choice and endpoint definition are central caveats.

## Mechanism

Activates the VEGFR2–Akt–eNOS pathway (with upstream Src / Caveolin-1 signaling), driving nitric-oxide–dependent angiogenesis; also modulates growth-factor signaling and the gut–brain axis.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 Da |
| PubChem CID | [9941957](https://pubchem.ncbi.nlm.nih.gov/compound/9941957) |

## Sequence

```
GEPPPGKPADDAGLV
```

## Research areas

Studied in: Tendinopathy, Wound healing, IBD models.

Guides on this site:

- [Wound Healing & Tissue Repair](https://www.americanpeptide.com/research-areas/wound-healing): Regenerative peptides studied for soft-tissue, tendon, and vascular repair.
- [Immune & Inflammation](https://www.americanpeptide.com/research-areas/immune-inflammation): Thymic and host-defense peptides studied for immune modulation.

## Key research

- Angiogenesis mechanism — repair effects are attributed largely to activation of the VEGFR2–Akt–eNOS pathway (with upstream Src / Caveolin-1 signaling), increasing nitric-oxide–dependent new-vessel formation in hypovascular tissue such as tendon.
- Nitric-oxide modulation — the Sikiric research group first linked the gastric-protective effect to NO generation; subsequent L-NAME / L-arginine co-treatment studies support NO involvement across multiple tissue-injury models.
- Tendon, ligament & GI repair — the most-replicated preclinical domains, spanning musculoskeletal injury and ulcer / inflammatory-bowel models.
- Compared to TB-500 — both are studied as healing peptides but differ mechanistically: BPC-157 is perfusion-led (angiogenesis / NO) while TB-500 is migration-led (actin regulation), which is why the two are often examined together.
- Evidence quality — extensive rodent data (much of it from a single research group) but no controlled human trials; not FDA-approved.

## Storage, handling & synthesis

**Storage.** Lyophilized: store frozen and protected from light for long-term stability. Reconstituted: refrigerate at 2–8 °C and use within weeks.

**Handling.** Reconstitute gently and avoid shaking; protect from heat, light, and repeated freeze–thaw.

**Synthesis.** At 15 residues BPC-157 is a comparatively short synthesis, which makes it cheap to produce — and cheap to fake. The short, low-cost sequence is exactly why the market is flooded with under-characterized material; a batch-specific certificate of analysis is the only way to tell real from filler.

## FAQs

### What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in gastric juice, studied in preclinical models for tissue repair and cytoprotection.

### What is BPC-157 studied for?

Research contexts include tendon, ligament, and muscle repair, gastrointestinal protection, and angiogenesis — almost entirely in cell and animal models.

### Is BPC-157 FDA approved?

No. BPC-157 is not approved for any medical use and the evidence base is preclinical. This page is a research and educational reference only.

### What is the proposed mechanism?

Studies point to upregulation of the VEGFR2 receptor and modulation of nitric-oxide and growth-factor pathways, though the mechanism is not fully established.

## Latest research

Recent trials and publications mentioning BPC-157, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [BPC 157 for Acute Hamstring Muscle Strain Repair](https://clinicaltrials.gov/study/NCT07437547) — RECRUITING · PHASE2 · NCT07437547
- [PCO-02 - Safety and Pharmacokinetics Trial](https://clinicaltrials.gov/study/NCT02637284) — UNKNOWN · PHASE1 · NCT02637284

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/bpc-157
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.